Maria Teresa Puras

• Nominated and chosen to form part of highly selective elite National Accounts Leadership Development Program 2023-2024
• Responsible for Puerto Rico launch of CYLTEZO/ADALIMUMAB-ADBM, specialty treatment for Immunology
• Spearheaded and executed a comprehensive strategic plan, Specialty Pharmacy distribution channel education that resulting in Puerto Rico ranking #1 for 2024
• Responsible for access in local carveout accounts with wins in MMM, SSS and MCS within a 2-month period
• Long Standing relationships within Pharmacy Benefit Managers(PBM), P&T committees thereby creating a collaborative network to implement coverage criteria aligned to the appropriate patient types
• Cross functional collaboration with internal and external partners to ensure local patient needs including, Reimbursement specialist, Regional Account Executive, Medical Liaison, Clinical Educator, Marketing lead to ensure Spanish support materials, Specialty Pharmacy Consultant, Zone Director, Associate Director
• Formulated a robust distribution and specialty pharmacy strategy ensuring widespread product access across all channels overcoming barriers which led to stock in all mayor accounts
• Responsible for education and representation in local Dermatology, Gastroenterology and Rheumatology conventions for CYLTEZO and SPEVIGO
• Ultra-Rare Disease rotation to support local SPEVIGO efforts identifying infusion center, ensuring access which led to the infusion of GPP patient within 1 week of diagnosis by dermatologist
• Member of the Zone Advisory Council with Commercial business lead to ensure patient and customer concerns are addressed
• Liaised with customers, management, and sales team to better understand customer needs and recommend appropriate solutions.
• Developed innovative strategies for clients, resulting in increased revenue and business growth.
• Analyzed data sets to identify trends and opportunities for process improvements within client organizations.
• Assisted clients in navigating complex industry challenges with strategic recommendations.

Responsible for the Launch of the Respiratory and Cardiometabolic Portfolio including 10 products including Tiotroprium, Anticoagulant, DPP4, SGLT2 and FDCs within the different therapeutic areas .

Developed strategy to combat increased competitive presence within territory.

• Cultivated strong relationships with key industry partners to foster collaboration and drive business success.
• Winner PC 2022, 4th in Nation
• Winner 2022 Innovation Award for the streamlined operations for increased efficiency with the implementation of new processes and technology tools. VAE icon.
• Chosen as Regional Advisory Council member since 2020
• PC Award Winner: GOLD 2021, 2018, 2017
• PC Award Winner: SILVER 2016, 2015, 2009
• Launched SPIRIVA for COPD and was responsible for the addition to Pavia Hospital System formulary in 2024
• Launched PRADAXA and collaborated with the Regional Account Executive to have on MMM formulary and Pavia Hospital system within 6 months
• Speaker Liasion lead since 2004
• Expanded market presence through development and implementation of teaching institution program and effective brand positioning efforts.

Responsible for the enhancing the sales and ethical promotion of VIOXX, FOSAMAX, SINGULAIR, and COZAAR in the San Juan territory

• Achieved and maintained #1 rank in sales for VIOXX leading the Nation in Market share.
• Provided Clinical presentations to Medical students, residents and fellows within the San Juan Hospital and teaching institutions
• Supported the marketing in coordination and execution of promotional activities standing out as a Speaker Liaison with over 40 programs for the year